{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:07:45Z","timestamp":1779084465007,"version":"3.51.4"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This research aims to investigate the performance of macrolide antibiotics for the treatment of Mycoplasma pneumoniae pneumonia (MPP) in children with or without Mycoplasma pneumoniae (MP) resistance genes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study enrolled pediatric MPP patients admitted to the Department of Pediatrics at the hospital between January 2023 and December 2023. Macrolide resistance genes in MP were tested using throat swab and bronchoalveolar lavage fluid samples, and patients were classified into the macrolide-resistant MP (MRMP) group and the macrolide-susceptible MP (MSMP) group based on the results of v-domain point mutations. After sampling, all patients received standard macrolide treatment. The baseline characteristics and laboratory examination results were documented and compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 217 MPP patients were included, among these patients, 188 with v-domain point mutations (all A2063 G point mutation) were classified as MRMP (99 males, 5.84\u2009\u00b1\u20092.81 years) with an MRMP rate of 86.6%, the remaining 29 were classified as MSMP (14 males, 6.79\u2009\u00b1\u20094.08 years). No significant difference in baseline characteristics was observed between the patients of the two groups. While the MP DNA load was higher in both throat swabs (3.97\u2009\u00b1\u20090.64 vs. 3.65\u2009\u00b1\u20090.77;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.039) and bronchoalveolar lavage fluid (4.11\u2009\u00b1\u20090.58 vs. 3.18\u2009\u00b1\u20090.77;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.001) samples obtained from MRMP patients, the duration of macrolide therapy (7.66\u2009\u00b1\u20091.95 vs. 6.38\u2009\u00b1\u20092.37 days,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.002) were also longer in MRMP patients. The incidence of severe Mycoplasma pneumoniae pneumonia (SMPP) was 5.8% in the MRMP group and 17.2% in the MSMP group (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.071).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MP DNA load and the duration of macrolide use are higher in MRMP patients, while no significant difference was observed between the prevalence of adverse events and clinical characteristics after treatment, indicating that macrolide treatment demonstrates comparable clinical effectiveness in both MRMP and MSMP patients. However, the association between MP DNA load and duration of macrolide use should be further evaluated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2026.1744694","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:42:18Z","timestamp":1779082938000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the therapeutic performance of macrolide antibiotics on macrolide-resistant or macrolide-susceptible Mycoplasma pneumoniae pneumonia children"],"prefix":"10.3389","volume":"14","author":[{"given":"Yi-Qing","family":"Qiu","sequence":"first","affiliation":[{"name":"Department of Pediatrics, The First People's Hospital of Foshan","place":["Foshan, Guangdong Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Qian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The First People's Hospital of Foshan","place":["Foshan, Guangdong Province, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12879-021-05830-4","article-title":"Clinical characteristics of refractory Mycoplasma pneumoniae pneumonia in children treated with glucocorticoid pulse therapy","volume":"21","author":"Zhu","year":"2021","journal-title":"BMC Infect Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1007\/s10096-021-04171-z","article-title":"Mycoplasma pneumoniae may cause dyspnoea and hospitalisations in young healthy adults","volume":"40","author":"Mets\u00e4l\u00e4","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.3390\/jcm11102824","article-title":"Refractory Mycoplasma pneumoniae pneumonia in children: early recognition and management","volume":"11","author":"Tong","year":"2022","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.21037\/jtd-20-2256","article-title":"Fluoroquinolone and no risk of Achilles-tendinopathy in childhood pneumonia under eight years of age-a nationwide retrospective cohort","volume":"13","author":"Kim","year":"2021","journal-title":"J Thorac Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3969\/j.issn.1672-3384.2023.08.012","article-title":"Analysis of risk factors and construction of risk assessment model for macrolide antibiotics resistance in children with mycoplasma pneumonia","volume":"21","author":"Chen","year":"2023","journal-title":"J Clin Pharmacol Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.3201\/eid2706.203206","article-title":"Macrolide-resistant Mycoplasma pneumoniae infections in children, Ohio, USA","volume":"27","author":"Lanata","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1002\/ppul.25298","article-title":"Cases of macrolide-resistant Mycoplasma pneumoniae pneumonia-associated pulmonary thromboembolism","volume":"56","author":"Kim","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e3160","DOI":"10.1097\/md.0000000000003160","article-title":"Clonal spread of a unique strain of macrolide-resistant Mycoplasma pneumoniae within a single family in Italy","volume":"95","author":"Chironna","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/s2666-5247(22)00190-2","article-title":"Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it?","volume":"3","author":"Sauteur","year":"2022","journal-title":"Lancet Microbe"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1093\/jac\/dkac170","article-title":"Global prevalence of resistance to macrolides in Mycoplasma pneumoniae: a systematic review and meta-analysis","volume":"77","author":"Wang","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"B11","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s12519-024-00831-0","article-title":"Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children","volume":"20","author":"Wang","year":"2024","journal-title":"World J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s00284-022-03103-0","article-title":"Insight into the pathogenic mechanism of Mycoplasma pneumoniae","volume":"80","author":"Hu","year":"2022","journal-title":"Curr Microbiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1135228","DOI":"10.3389\/fcimb.2023.1135228","article-title":"Clinical features and \u201cearly\u201d corticosteroid treatment outcome of pediatric Mycoplasma pneumoniae pneumonia","volume":"13","author":"Liu","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front Microbiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1038\/s41598-024-55311-2","article-title":"Observational retrospective clinical study on clinical features of macrolide-resistant Mycoplasma pneumoniae pneumonia in Chinese pediatric cases","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.3390\/jcm11020306","article-title":"Clinical characteristics of macrolide-refractory Mycoplasma pneumoniae pneumonia in Korean children: a multicenter retrospective study","volume":"11","author":"Choi","year":"2022","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4168\/aair.2017.9.4.340","article-title":"Macrolide resistance and its impacts on M. pneumoniae pneumonia in children: comparison of two recent epidemics in Korea","volume":"9","author":"Kim","year":"2017","journal-title":"Allergy Asthma Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3760\/cma.j.cn112140-20240722-00503","article-title":"Evidence-based guideline for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2023)","volume":"62","year":"2024","journal-title":"Chin J Pediatr"},{"key":"B19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3760\/cma.j.issn.1674-2397.2025.06.001","article-title":"Guidelines for the diagnosis and treatment of Mycoplasma pneumoniae pneumonia in children (2025 edition)","volume":"18","year":"2025","journal-title":"Chin J Clin Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2482703","DOI":"10.1080\/22221751.2025.2482703","article-title":"Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022\u20132024: a nationwide cross-sectional study of over 1.6 million cases","volume":"14","author":"Sun","year":"2025","journal-title":"Emerg Microbes Infect"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.2147\/idr.S370126","article-title":"Antimicrobial susceptibility profiles and genetic characteristics of Mycoplasma pneumoniae in Shanghai, China, from 2017 to 2019","volume":"15","author":"Wang","year":"2022","journal-title":"Infect Drug Resist"},{"key":"B22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ijid.2019.03.028","article-title":"Molecular characterization and analysis of Mycoplasma pneumoniae among patients of all ages with community-acquired pneumonia during an epidemic in China","volume":"83","author":"Qu","year":"2019","journal-title":"Int J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3969\/j.issn.1004-583X.2023.03.007","article-title":"Mycoplasma pneumoniae infection in Chengdu in 2021: an epidemiological study","volume":"38","author":"Zhang","year":"2023","journal-title":"Clin Focus"},{"key":"B24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3969\/j.issn.1673-5501.2016.05.008","article-title":"The clinical characteristics of macrolide-resistant Mycoplasma pneumoniae pneumonia in children: a case-control study","volume":"11","author":"Feng","year":"2016","journal-title":"Chin J Evid Based Pediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3969\/j.issn.0253-9802.2023.05.009","volume":"54","author":"Li","year":"2023","journal-title":"J New Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"102095","DOI":"10.1016\/j.pupt.2021.102095","article-title":"The immunomodulatory effects of macrolide antibiotics in respiratory disease","volume":"71","author":"Pollock","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1186\/s12879-019-4667-y","article-title":"High Mycoplasma pneumoniae loads and persistent long-term Mycoplasma pneumoniae DNA in lower airway associated with severity of pediatric Mycoplasma pneumoniae pneumonia","volume":"19","author":"Liu","year":"2019","journal-title":"BMC Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/14787210.2018.1414599","article-title":"Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children","volume":"16","author":"Lee","year":"2018","journal-title":"Expert Rev Anti Infect Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.jmii.2023.01.010","article-title":"The clinical significance of and the factors associated with macrolide resistance and poor macrolide response in pediatric Mycoplasma pneumoniae infection: a retrospective study","volume":"56","author":"Yen","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"B30","doi-asserted-by":"publisher","first-page":"010502","DOI":"10.11613\/bm.2021.010502","article-title":"Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies","volume":"31","author":"Serdar","year":"2021","journal-title":"Biochem Med (Zagreb)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1189647","DOI":"10.3389\/fimmu.2023.1189647","article-title":"Immune response plays a role in Mycoplasma pneumoniae pneumonia","volume":"14","author":"Zhu","year":"2023","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41577-020-00464-0","article-title":"Glucocorticoids in T cell development, differentiation and function","volume":"21","author":"Taves","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1181402","DOI":"10.3389\/fcimb.2023.1181402","article-title":"The clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic","volume":"13","author":"Jiang","year":"2023","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1744694\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T05:42:24Z","timestamp":1779082944000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2026.1744694\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":33,"alternative-id":["10.3389\/fped.2026.1744694"],"URL":"https:\/\/doi.org\/10.3389\/fped.2026.1744694","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"article-number":"1744694"}}